Mama mia_老虎社区_美港股上老虎

JB0112
2021-10-12

Mama mia

Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought<blockquote>凯西·伍德(Cathie Wood)去翻垃圾箱：她刚刚购买的3只下跌股票</blockquote>

All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.

Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought<blockquote>凯西·伍德(Cathie Wood)去翻垃圾箱：她刚刚购买的3只下跌股票</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":826512098,"tweetId":"826512098","gmtCreate":1634037083365,"gmtModify":1634037199801,"author":{"id":3585877031221506,"idStr":"3585877031221506","authorId":3585877031221506,"authorIdStr":"3585877031221506","name":"JB0112","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Mama mia</body></html>","htmlText":"<html><head></head><body>Mama mia</body></html>","text":"Mama mia","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/826512098","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","kind":"news","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=zh_CN&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought<blockquote>凯西·伍德(Cathie Wood)去翻垃圾箱：她刚刚购买的3只下跌股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points<blockquote>要点</blockquote> <ul> <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li> <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li> <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li> </ul> <blockquote><ul><li>伍德最近购买了陷入困境的合成生物学股票Ginkgo Bioworks的股票，此前一份卖空报告将其推低。</li><li>ARK Invest ETF还增持了一家名为Signify Health的医疗保健中间商的股票。</li><li>Beam Therapeutics是一家拥有比基因编辑更安全替代品的生物技术公司，上周也每天都进入ARK Innovation ETF。</li></ul></blockquote> Do you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.<blockquote>你知道当股市击败他们最喜欢的股票时，自信的投资者会怎么做吗？他们利用便宜的价格，买得更多。</blockquote> Last week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.<blockquote>上周对于一些生命科学和医疗保健股票来说是糟糕的一周。这并没有阻止ARK Invest创始人兼首席执行官凯西·伍德(Cathie Wood)增持一些她最喜欢的股票头寸。</blockquote> Here's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).<blockquote>这就是伍德最近购买更多股票的原因银杏生物工程（纽约证券交易所代码：DNA），表示健康（纽约证券交易所代码：SGFY），以及光束治疗（纳斯达克：梁）。</blockquote> <img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 1. Ginkgo Bioworks<blockquote>1.银杏生物工程</blockquote> Wood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.<blockquote>早在一家特殊目的收购公司于9月中旬将这家合成生物学公司上市之前，伍德就一直是该公司的忠实粉丝。上周，伍德多次增持Ark Invests的Ginkgo Bioworks头寸，尽管该股面临很大压力。</blockquote> A lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.<blockquote>最近，一位卖空者的长篇谩骂凸显了该公司缺乏盈利能力，并重创了该股。Ginkgo Bioworks正在构建一个平台，该平台将使各种企业能够随意对活细胞进行编程。不幸的是，对此类服务的需求远没有Gingko Bioworks投资者希望的那么强劲。</blockquote> Ginkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.<blockquote>Ginkgo Bioworks试图通过投资初创企业来解决合成生物学服务需求疲软的问题。不过，该公司没有交出现金，而是发放银杏币，企业只能用这些银杏币来支付代工服务费用。</blockquote> Years ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.<blockquote>年前，全球领先的合成生物学公司，阿米里斯（纳斯达克：AMRS），意识到不能依赖第三方来满足需求。不过，由于自有品牌在健康和美容领域的销售，Amyris终于开始产生可持续的利润。</blockquote> Gingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.<blockquote>Gingko Bioworks并不是第一家惨痛认识到代工服务利润不高的合成生物学公司。这是因为设计一种能够产生特定成分的有机体是这项业务中容易的部分。然而，使此类投资值得的规模生产是Gingko Bioworks尚未解决的挑战。</blockquote> <img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 2. Signify Health<blockquote>2.昕诺飞健康</blockquote> This relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.<blockquote>这只相对较新的医疗保健股自2月份上市后不久达到峰值以来已下跌约54%。不过，木头没有动摇。Ark Invest基金上周每天都购买更多Signify Health股票。</blockquote> Signify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.<blockquote>Signify Health是一家中间商，与医疗保健提供商和医疗保健福利经理合作，例如国歌保持较低的平均成本。Signify Health目前最受欢迎的服务包括对患者进行家庭评估，以减少再入院。</blockquote> Ever since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.<blockquote>自2010年患者保护与平价医疗法案通过以来，医疗保健提供者越来越有可能为特定的健康事件（如白内障摘除手术或膝关节置换）获得固定费率。通过让患者尽可能安全地呆在家里，Signify Health可以为保险公司节省一大笔钱。</blockquote> Signify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.<blockquote>Signify Health的医疗保健支出管理方法对Signify及其客户来说效果很好。2021年上半年，该公司公布的调整后息税折旧摊销前利润(EBITDA)达到了令人印象深刻的8900万美元。</blockquote> <img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 3. Beam Therapeutics<blockquote>3.光束治疗学</blockquote> This biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.<blockquote>这只生物科技股于2020年初上市，是这份名单上最古老的股票。不过，自7月份达到峰值以来，其价值已下跌约37%。伍德没有被最近的下滑吓倒，将Beam Therapeutics的股票添加到方舟创新ETF（NYSEMKT：ARKK）上周的每一天。</blockquote> Wood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.<blockquote>伍德对这家公司的碱基编辑技术很感兴趣。大多数基因编辑技术涉及在特定位点切割DNA链以去除或插入核苷酸序列。不幸的是，这种方法伴随着很多风险。Beam Therapeutics采用碱基编辑技术，可以将胸腺嘧啶转化为腺嘌呤或将胞嘧啶转化为鸟嘌呤。</blockquote> Beam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.<blockquote>Beam Therapeutics的方法应该比断裂和修复DNA链的问题小得多。对更安全的基因编辑方法的需求也在上升。破坏DNA的实验性基因疗法引发的一系列安全恐慌，包括异体基因最近的内爆清楚地表明，迫切需要一种更好的基因编辑方法。</blockquote> Beam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.<blockquote>Beam Therapeutics、Signify Health和Ginkgo Bioworks本月初被列入伍德的买入名单。让我们看看随着十月份的进展，她是否会继续增加这些职位。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought<blockquote>凯西·伍德(Cathie Wood)去翻垃圾箱：她刚刚购买的3只下跌股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought<blockquote>凯西·伍德(Cathie Wood)去翻垃圾箱：她刚刚购买的3只下跌股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-10-12 17:52\n\n</h4>\n</header>\n<article>\nKey Points<blockquote>要点</blockquote> <ul> <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li> <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li> <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li> </ul> <blockquote><ul><li>伍德最近购买了陷入困境的合成生物学股票Ginkgo Bioworks的股票，此前一份卖空报告将其推低。</li><li>ARK Invest ETF还增持了一家名为Signify Health的医疗保健中间商的股票。</li><li>Beam Therapeutics是一家拥有比基因编辑更安全替代品的生物技术公司，上周也每天都进入ARK Innovation ETF。</li></ul></blockquote> Do you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.<blockquote>你知道当股市击败他们最喜欢的股票时，自信的投资者会怎么做吗？他们利用便宜的价格，买得更多。</blockquote> Last week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.<blockquote>上周对于一些生命科学和医疗保健股票来说是糟糕的一周。这并没有阻止ARK Invest创始人兼首席执行官凯西·伍德(Cathie Wood)增持一些她最喜欢的股票头寸。</blockquote> Here's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).<blockquote>这就是伍德最近购买更多股票的原因银杏生物工程（纽约证券交易所代码：DNA），表示健康（纽约证券交易所代码：SGFY），以及光束治疗（纳斯达克：梁）。</blockquote> <img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 1. Ginkgo Bioworks<blockquote>1.银杏生物工程</blockquote> Wood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.<blockquote>早在一家特殊目的收购公司于9月中旬将这家合成生物学公司上市之前，伍德就一直是该公司的忠实粉丝。上周，伍德多次增持Ark Invests的Ginkgo Bioworks头寸，尽管该股面临很大压力。</blockquote> A lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.<blockquote>最近，一位卖空者的长篇谩骂凸显了该公司缺乏盈利能力，并重创了该股。Ginkgo Bioworks正在构建一个平台，该平台将使各种企业能够随意对活细胞进行编程。不幸的是，对此类服务的需求远没有Gingko Bioworks投资者希望的那么强劲。</blockquote> Ginkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.<blockquote>Ginkgo Bioworks试图通过投资初创企业来解决合成生物学服务需求疲软的问题。不过，该公司没有交出现金，而是发放银杏币，企业只能用这些银杏币来支付代工服务费用。</blockquote> Years ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.<blockquote>年前，全球领先的合成生物学公司，阿米里斯（纳斯达克：AMRS），意识到不能依赖第三方来满足需求。不过，由于自有品牌在健康和美容领域的销售，Amyris终于开始产生可持续的利润。</blockquote> Gingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.<blockquote>Gingko Bioworks并不是第一家惨痛认识到代工服务利润不高的合成生物学公司。这是因为设计一种能够产生特定成分的有机体是这项业务中容易的部分。然而，使此类投资值得的规模生产是Gingko Bioworks尚未解决的挑战。</blockquote> <img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 2. Signify Health<blockquote>2.昕诺飞健康</blockquote> This relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.<blockquote>这只相对较新的医疗保健股自2月份上市后不久达到峰值以来已下跌约54%。不过，木头没有动摇。Ark Invest基金上周每天都购买更多Signify Health股票。</blockquote> Signify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.<blockquote>Signify Health是一家中间商，与医疗保健提供商和医疗保健福利经理合作，例如国歌保持较低的平均成本。Signify Health目前最受欢迎的服务包括对患者进行家庭评估，以减少再入院。</blockquote> Ever since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.<blockquote>自2010年患者保护与平价医疗法案通过以来，医疗保健提供者越来越有可能为特定的健康事件（如白内障摘除手术或膝关节置换）获得固定费率。通过让患者尽可能安全地呆在家里，Signify Health可以为保险公司节省一大笔钱。</blockquote> Signify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.<blockquote>Signify Health的医疗保健支出管理方法对Signify及其客户来说效果很好。2021年上半年，该公司公布的调整后息税折旧摊销前利润(EBITDA)达到了令人印象深刻的8900万美元。</blockquote> <img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 3. Beam Therapeutics<blockquote>3.光束治疗学</blockquote> This biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.<blockquote>这只生物科技股于2020年初上市，是这份名单上最古老的股票。不过，自7月份达到峰值以来，其价值已下跌约37%。伍德没有被最近的下滑吓倒，将Beam Therapeutics的股票添加到方舟创新ETF（NYSEMKT：ARKK）上周的每一天。</blockquote> Wood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.<blockquote>伍德对这家公司的碱基编辑技术很感兴趣。大多数基因编辑技术涉及在特定位点切割DNA链以去除或插入核苷酸序列。不幸的是，这种方法伴随着很多风险。Beam Therapeutics采用碱基编辑技术，可以将胸腺嘧啶转化为腺嘌呤或将胞嘧啶转化为鸟嘌呤。</blockquote> Beam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.<blockquote>Beam Therapeutics的方法应该比断裂和修复DNA链的问题小得多。对更安全的基因编辑方法的需求也在上升。破坏DNA的实验性基因疗法引发的一系列安全恐慌，包括异体基因最近的内爆清楚地表明，迫切需要一种更好的基因编辑方法。</blockquote> Beam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.<blockquote>Beam Therapeutics、Signify Health和Ginkgo Bioworks本月初被列入伍德的买入名单。让我们看看随着十月份的进展，她是否会继续增加这些职位。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SGFY":"Signify Health, Inc.","ARKK":"ARK Innovation ETF","BEAM":"Beam Therapeutics, Inc.","DNA":"Ginkgo Bioworks Holdings Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1,"symbols_score_info":{"ARKK":0.9,"BEAM":0.9,"DNA":0.9,"SGFY":0.9}},"isVote":1,"tweetType":1,"viewCount":2827,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}